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A 42-year-old hypothyroid shepherd presented with a progressive abdominal lump accompanied by nausea and abdominal fullness. In ad-
dition, he had worsening hypothyroidism, despite supranormal doses of thyroxine. Computed tomography of the abdomen was suggestive 
of a mass lesion in relation to the stomach. A resection of the mass was done and the histopathology was suggestive of gastrointestinal 
stromal tumor. After surgery, the patient became euthyroid. We believe the patient had consumptive hypothyroidism due to the tumor.
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Gastrointestinal stromal tumors (GIST) are me­
senchymal tumors that are believed to originate from 
the interstitial cells of Cajal or from mesenchymal 
stem cells present throughout the body. Owing to the 
physical effects of the tumor, the usual presentation 
can be abdominal discomfort, bleeding, nausea, 
vomiting, or early satiety. Very rarely do these tumors 
present with paraneoplastic syndrome. We report the 
case of a patient who had hypothyroidism due to a GIST 
of the stomach, which resolved after surgery.
A 42­year­old shepherd was referred to our hospital 
by his internist with the chief complaints of awareness 
of a progressive upper abdominal lump for 2 months 
and postprandial nausea with abdominal fullness for 
2 weeks. The patient was a known case of hypothy­
roidism, and had been on 25 µg of thyroxine (T4) for 
the past 15 months, but for the past 1 month, his se­
rum thyroid stimulating hormone (TSH) levels failed 
to return to previous levels despite taking 200 µg of T4. 
His most recent thyroid profile at the time was, TSH — 
49 µIU/ml, triiodothyronine (T3) — 0.37 ng/ml, T4 — 
4.3 µg/dl and reverse T3 — 292.4 ng/dl (normal range: 
TSH — 0.30–0.50 µIU/ml, T3 — 0.60–1.81 ng/ml, T4 — 
5.01 to 12.45 µg/dl and reverse T3 — 10–40 ng/dl). The 
patient had been compliant with medication and follow 
up. The patient was a teetotaller, and had no history 
of tobacco use. On examination of the abdomen, there 
was a 10 × 6 cm intra­abdominal lump present in the 
epigastrium, extending to the left hypochondrium, 
umbilical and the left lumbar regions. The lump was 
firm, non­tender, non­pulsatile, and mobile. Labora­
tory tests, including a complete blood cell count, blood 
biochemistry, liver enzymes, and serum amylase and 
lipase levels, were within normal limits. On computed 
tomography of the abdomen, a solid mass of size 
14.8 × 9.6 cm with heterogeneous non­enhancing 
low attenuation areas was identified in relation to the 
stomach (Fig. 1). On upper gastrointestinal endo­
scopy, a submucosal mass lesion was found in relation 
to the posterior wall of the stomach, without evidence 
of mucosal involvement. The patient underwent a distal 
gastrectomy with retrieval of a gastric mass arising from 
the posterior wall of the stomach without rupture of the 
mass during handling (Fig. 2). Other solid organs were 
normal. No lymphadenopathy or ascites was present.
Fig. 1. Computed tomography of the abdomen showing a solid 
mass of size 14.8 × 9.6 cm with heterogeneous non enhancing 
low attenuation areas identified in relation to the stomach
Submitted: October 04, 2016. 
*Correspondence: E-mail: drtusharpatial@gmail.com 
Abbreviations used: GIST — gastrointestinal stromal tumors; T3 — 
triiodothyronine; T4 — thyroxine; TSH — thyroid stimulating hormone.
Exp Oncol 2017
39, 4, 319–321
CASE REPORT
320 Experimental Oncology 39, 319–321, 2017 (December) Experimental Oncology 39, 319–321, 2017 (December) 321
A peculiar consequence of GIST is consumptive hypo­
thyroidism. First reported in children with infantile hae­
mangiomas, this condition results from accelerated 
degradation of circulating thyroid hormone at rates 
higher than the synthetic capacity of the normally 
stimulated thyroid gland. In cases of tyrosine kinase 
inhibitor naive patients, consumptive hypothyroidism 
is caused by overexpression of the thyroid hormone­
inactivating enzyme iodothyronine deiodinase 3. The 
diagnosis of consumptive hypothyroidism requires 
evidence of either elevated levels of serum reverse 
T3 or supranormal requirements for exogenous thyroid 
hormone [8]. In our patient, the patient’s requirement 
for supranormal doses of T4 was abolished soon after 
surgery, thus supporting this diagnosis.
On contrast­enhanced computed tomography, 
peripheral enhancement is present in the 75% of the 
cases of GIST. This represents an enhancement of pe­
ripheral areas of viable tumor. However, in a minority 
of patient’s areas of low attenuation may be present 
corresponding to haemorrhage, necrosis, or cyst for­
mation, as present in our case. We do not believe this 
is of consequence with respect to consumptive hypo­
thyroidism, as the imaging finding has been described 
without the paraneoplastic syndrome as well [9].
Surgery has been treatment of choice with 60% 
of patients being cured by surgery alone. Laparo­
scopic resection is considered a feasible procedure 
for patients with gastric GIST 5 cm or smaller, if not 
contraindicated by comorbidities. Locally advanced 
GIST may be candidates for surgical resection after 
neo­adjuvant treatment with Imatinib, a c­Kit inhibitor. 
In cases of inoperable, metastatic or recurrent GIST, 
Imatinib remains the first­line treatment [1, 10].
Although hypothyroidism is a frequent clinical 
scenario, the astute clinician must remember that hy­
pothyroidism can often be the herald of a much more 
sinister diagnosis such as a GIST. In cases of patients 
requiring supranormal doses of T4, a measurement 
of reverse T3 should be considered to establish the 
diagnosis of consumptive hypothyroidism.
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Fig. 2. Gross pathology specimen of the removed GIST, following 
a distal gastrectomy, with tumor free margins
On macroscopic examination, there was a solitary, 
round tumor measuring 11 × 8 × 6 cm in size. The 
lesion was well demarcated and had a pseudocap­
sule. On cut sectioning, the surface was mostly solid 
with a few cystic areas. Interspersed within were foci 
of necrosis and hemorrhage. Microscopic evaluation 
revealed a cellular proliferation of spindle­shaped cells 
with high nucleus:cytoplasm ratio. Cellular and nuclear 
pleomorphism was also present. Few areas of necrosis 
were also seen. Mitotic figures were seen occasionally 
embedded within areas of increased mitosis (9/50 high 
power field) (Fig. 3–5). On immunohistochemistry, the 
tissue was positive for CD117 (Fig. 6), but negative for 
desmin and S­100. Based on the macroscopic findings 
(size > 10 cm), histopathology (mitosis > 5/50 high 
power field) and immunohistochemistry a diagnosis 
of the GIST of the stomach with a high risk of neoplastic 
progression was made. The patient had an unevent­
ful recovery and was discharged 3 days after surgery 
on adjuvant imatinib mesylate. Post­operative thyroid 
function tests after 6 weeks were, TSH — 3.9 µIU/ml, 
T3 — 0.74 ng/ml, T4 — 7.2 µg/dl, and reverse T3 — 
252.3 ng/dl. After gradual reduction of exogenous T4, 
the drug has been withdrawn and the patient has been 
euthyroid since.
Fig. 3. Microphotograph of gastrectomy specimen (hemato­
xylin­eosin) showing features of a spindle cell type GIST with 
nuclear pleomorphism
DISCUSSION
The median age of GIST presentation is 55–60 years 
and these tumors represent 80% of all mesenchymal 
gastrointestinal tumors and 0.1–3% of all gastrointe­
stinal malignancies [1]. About 70% of the patients with 
GIST are symptomatic, 20% are asymptomatic and 
in 10% the lesions are detected only at autopsy. The 
tumor may present as abdominal discomfort, bleeding, 
nausea, vomiting, or early satiety. Tumor spread is usu­
ally intra­abdominal, and metastasis to lymph nodes 
is rare. Symptoms are usually dependant on the site 
involved, with the most common being the stomach 
(60%) and the small intestine (30–20%) [2].
Although rare, paraneoplastic syndromes have 
been described with GIST. These include autoimmune 
haemolytic anaemia, hypoglycaemia, hyponatremia, 
nephrotic syndrome, headache and diplopia [3–7]. 
Fig. 4. Microphotograph of specimen (hematoxylin­eosin) 
showing normal gastric mucosa with underlying spindle­
shaped cells
Fig. 5. Microphotograph of the tumor (hematoxylin­eosin) at low 
magnification of microscope
Fig. 6. Microphotograph of CD117 expression in tumor cells
Copyright © Experimental Oncology, 2017
